600267 海正药业
已收盘 08-11 15:00:00
资讯
新帖
简况
异动快报:海正药业(600267)8月10日9点41分触及涨停板
证券之星 · 08-10 09:45
异动快报:海正药业(600267)8月10日9点41分触及涨停板
每周股票复盘:海正药业(600267)5产品拟中选集采
证券之星 · 08-09
每周股票复盘:海正药业(600267)5产品拟中选集采
8月7日海正药业涨9.98%,大成丰享回报混合A基金重仓该股
证券之星 · 08-07
8月7日海正药业涨9.98%,大成丰享回报混合A基金重仓该股
8月4日海正药业涨6.39%,大成丰享回报混合A基金重仓该股
证券之星 · 08-04
8月4日海正药业涨6.39%,大成丰享回报混合A基金重仓该股
海正药业(600267.SH):他克莫司胶囊等5个产品拟中选集中带量采购
智通财经 · 08-03
海正药业(600267.SH):他克莫司胶囊等5个产品拟中选集中带量采购
海正药业(600267.SH)子公司制剂产品磷酸氟达拉滨注射液获得美国FDA批准
智通财经 · 07-24
海正药业(600267.SH)子公司制剂产品磷酸氟达拉滨注射液获得美国FDA批准
海正药业:三箭齐发+战略瘦身,老牌药企重塑增长内核
中金财经 · 07-21
海正药业:三箭齐发+战略瘦身,老牌药企重塑增长内核
海正药业(600267)披露与艾缇亚签署产品独家授权许可及合作协议,7月20日股价上涨9.98%
证券之星 · 07-20
海正药业(600267)披露与艾缇亚签署产品独家授权许可及合作协议,7月20日股价上涨9.98%
海正药业与艾缇亚达成合作
格隆汇 · 07-20
海正药业与艾缇亚达成合作
异动快报:海正药业(600267)7月20日9点53分触及涨停板
证券之星 · 07-20
异动快报:海正药业(600267)7月20日9点53分触及涨停板
每周股票复盘:海正药业(600267)获来特莫韦片注册证
证券之星 · 07-19
每周股票复盘:海正药业(600267)获来特莫韦片注册证
海正药业(600267)披露引进TISA-818系统给药制剂权益协议,7月13日股价上涨5.2%
证券之星 · 07-13
海正药业(600267)披露引进TISA-818系统给药制剂权益协议,7月13日股价上涨5.2%
股市必读:海正药业(600267)预计2026年1-6月扣非后净利润盈利4.9亿元至5.3亿元
证券之星 · 07-13
股市必读:海正药业(600267)预计2026年1-6月扣非后净利润盈利4.9亿元至5.3亿元
每周股票复盘:海正药业(600267)上半年净利预增超100%
证券之星 · 07-12
每周股票复盘:海正药业(600267)上半年净利预增超100%
海正药业(600267)披露2026年半年度业绩预增公告,7月10日股价上涨3.26%
证券之星 · 07-10
海正药业(600267)披露2026年半年度业绩预增公告,7月10日股价上涨3.26%
海正药业:预计2026年1-6月扣非后净利润盈利4.9亿元至5.3亿元
证券之星 · 07-10
海正药业:预计2026年1-6月扣非后净利润盈利4.9亿元至5.3亿元
海正药业最新公告:预计2026年半年度净利润同比增长101%-117%
证券之星 · 07-10
海正药业最新公告:预计2026年半年度净利润同比增长101%-117%
海正药业最新公告:签署TISA-818独家授权许可及合作协议
证券之星 · 07-03
海正药业最新公告:签署TISA-818独家授权许可及合作协议
海正药业(600267)披露来特莫韦原料药获上市批准通知书,6月30日股价下跌2.22%
证券之星 · 06-30
海正药业(600267)披露来特莫韦原料药获上市批准通知书,6月30日股价下跌2.22%
海正药业(600267.SH):来特莫韦原料药获批上市
智通财经 · 06-29
海正药业(600267.SH):来特莫韦原料药获批上市
加载更多
公司概况
公司名称:
浙江海正药业股份有限公司
所属行业:
医药制造业
上市日期:
2000-07-25
主营业务:
浙江海正药业股份有限公司的主营业务是化学原料药和制剂的研发、生产和销售业务。公司的主要产品是抗肿瘤药、抗感染药、心血管药、抗寄生虫药及兽药、内分泌药、其他药品、医药商业、CMO/CDMO/CRO业务、其他。公司入选中国医药工业信息中心“2025年中国医药研发产品线工业企业优秀案例”、2024年度中国医药工业百强榜、人民网“2025人民企业社会责任案例”;获得第90届药交会“首届创新药上市解决方案大赛”综合实力奖,入选2025中国制药工业TOP101榜单;荣膺EcoVadis铜牌认证,可持续发展实践获国际认可;子公司瀚晖制药荣获“浙江省先进级智能工厂”认定;澐生合成荣获BRCGSA级认证,打造合成生物学质量新标杆。
发行价格:
11.83
{"stockData":{"symbol":"600267","market":"SH","secType":"STK","nameCN":"海正药业","latestPrice":13.85,"timestamp":1786431601000,"preClose":14.24,"halted":0,"volume":108962440,"delay":0,"changeRate":-0.0274,"floatShares":1180000000,"shares":1180000000,"eps":0.595,"marketStatus":"已收盘","change":-0.39,"latestTime":"08-11 15:00:00","open":14.07,"high":14.28,"low":13.78,"amount":1526000000,"amplitude":0.0351,"askPrice":13.85,"askSize":437,"bidPrice":13.84,"bidSize":777,"shortable":0,"etf":0,"ttmEps":0.595,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786498200000},"marketStatusCode":5,"adr":0,"adjPreClose":14.24,"symbolType":"stock","openAndCloseTimeList":[[1786411800000,1786419000000],[1786424400000,1786431600000]],"highLimit":15.66,"lowLimit":12.82,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1180272096,"isCdr":false,"pbRate":1.83,"roa":"--","peRate":23.277311,"roe":"4.05%","epsLYR":0.46,"committee":0.421117,"marketValue":16347000000,"turnoverRate":0.0923,"status":1,"floatMarketCap":16347000000},"requestUrl":"/m/hq/s/600267","defaultTab":"news","newsList":[{"id":"2658609922","title":"异动快报:海正药业(600267)8月10日9点41分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2658609922","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658609922?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:45","pubTimestamp":1786326327,"startTime":"0","endTime":"0","summary":"证券之星8月10日盘中消息,9点41分海正药业(600267)触及涨停板。其所属行业化学制药目前上涨。领涨股为哈药股份。该股为医药商业,PD-1抑制剂,阿尔茨海默病概念热股,当日医药商业概念上涨2.04%,PD-1抑制剂概念上涨1.71%,阿尔茨海默病概念上涨1.39%。8月7日的资金流向数据方面,主力资金净流入1.88亿元,占总成交额25.71%,游资资金净流出8257.65万元,占总成交额11.28%,散户资金净流出1.06亿元,占总成交额14.43%。近5日资金流向一览见下表:海正药业主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000003927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600267","BK0060","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658556673","title":"每周股票复盘:海正药业(600267)5产品拟中选集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2658556673","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658556673?lang=zh_cn&edition=full","pubTime":"2026-08-09 01:10","pubTimestamp":1786209018,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘,海正药业报收于13.11元,较上周的11.58元上涨13.21%。本周,海正药业8月7日盘中最高价报13.11元,股价触及近一年最高点。海正药业当前最新总市值154.73亿元,在化学制药板块市值排名30/149,在两市A股市值排名1247/5205。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600267","BK0239","BK0188","BK0028","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657769615","title":"8月7日海正药业涨9.98%,大成丰享回报混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657769615","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657769615?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:36","pubTimestamp":1786091778,"startTime":"0","endTime":"0","summary":"证券之星消息,8月7日海正药业涨9.98%创60日新高,收盘报13.11元,换手率4.82%,成交量56.91万手,成交额7.32亿元。重仓海正药业的公募基金请见下表:根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共7家,其中持有数量最多的公募基金为大成基金的大成丰享回报混合A。大成丰享回报混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700027857.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","600267","BK0060","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656535054","title":"8月4日海正药业涨6.39%,大成丰享回报混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2656535054","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656535054?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:26","pubTimestamp":1785831983,"startTime":"0","endTime":"0","summary":"证券之星消息,8月4日海正药业涨6.39%,收盘报12.15元,换手率5.42%,成交量63.96万手,成交额7.67亿元。重仓海正药业的公募基金请见下表:根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共7家,其中持有数量最多的公募基金为大成基金的大成丰享回报混合A。大成丰享回报混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400027203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0060","600267","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656232990","title":"海正药业(600267.SH):他克莫司胶囊等5个产品拟中选集中带量采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2656232990","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656232990?lang=zh_cn&edition=full","pubTime":"2026-08-03 15:44","pubTimestamp":1785743076,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海正药业 发布公告,2026年7月31日,公司及全资子公司瀚晖制药有限公司参加了联合采购办公室组织的第十二批国家组织药品集中带量采购的投标工作,根据联采办当晚发布的《第12批国家组织药品集中带量采购拟中选结果公示》,公司及全资子公司瀚晖制药符合本次集中带量采购范围的5个产品拟中选本次集中带量采购。上述拟中选产品2025年度销售额合计4.26亿元,占公司2025年度营业收入的比例约为4.04%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0028","600267","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653700110","title":"海正药业(600267.SH)子公司制剂产品磷酸氟达拉滨注射液获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2653700110","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653700110?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:53","pubTimestamp":1784883217,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海正药业(600267.SH)发布公告,近日,公司全资子公司海正药业(杭州)有限公司(简称“海正杭州公司”)收到美国食品药品监督管理局(简称“美国FDA”)的通知,海正杭州公司向美国FDA申报的磷酸氟达拉滨注射液的新药简略申请(ANDA,即美国仿制药申请)已获得批准,意味着海正杭州公司可以在美国市场销售该产品。据悉,磷酸氟达拉滨注射液是一种核苷代谢抑制剂,适应症为:作为联合治疗方案的组成药物,用于治疗成人B细胞慢性淋巴细胞白血病(CLL);用于对既往接受至少1种含烷化剂的治疗方案治疗无效,或在治疗过程中出现疾病进展的成人B细胞慢性淋巴细胞白血病患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471931.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK0028","BK4585","BK0188","LABU","BK4588","600267","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653795102","title":"海正药业:三箭齐发+战略瘦身,老牌药企重塑增长内核","url":"https://stock-news.laohu8.com/highlight/detail?id=2653795102","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653795102?lang=zh_cn&edition=full","pubTime":"2026-07-21 18:30","pubTimestamp":1784629801,"startTime":"0","endTime":"0","summary":"亮眼的数据表现并非短期红利,而是海正药业深耕制药主业,创新药、原料药、宠物药三大板块协同发力,叠加公司主动战略瘦身、剥离低效资产的双重成果,这家老牌药企悄然完成转型升级,正式迈入发展新阶段。2026年上半年,海正药业对外转让浙江省医药工业有限公司100%股权,进一步聚焦主业。2026年上半年,海正药业预计实现扣非归母净利润4.9亿元至5.3亿元,同比增长52.54%至64.99%。海正药业此次主动瘦身,本质是国资药企回归产业本源的理性选择。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202607/21/20260721977262.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202607/21/20260721977262.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260721/32313949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0060","BK0028","600267","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652500211","title":"海正药业(600267)披露与艾缇亚签署产品独家授权许可及合作协议,7月20日股价上涨9.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652500211","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652500211?lang=zh_cn&edition=full","pubTime":"2026-07-20 22:15","pubTimestamp":1784556922,"startTime":"0","endTime":"0","summary":"截至2026年7月20日收盘,海正药业报收于12.45元,较前一交易日上涨9.98%,最新总市值为146.94亿元。该股当日开盘11.4元,最高12.45元,最低11.36元,成交额达12.28亿元,换手率为8.52%。近日,海正药业披露《2026年第二次临时股东会决议公告》。公告显示,公司于2026年7月20日召开2026年第二次临时股东会,审议通过《关于公司与艾缇亚(上海)制药有限公司签署产品独家授权许可及合作协议的议案》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000039486.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","600267","BK0188","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652528219","title":"海正药业与艾缇亚达成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2652528219","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652528219?lang=zh_cn&edition=full","pubTime":"2026-07-20 21:46","pubTimestamp":1784555160,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0188","BK0239","BK0060","BK0028","600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652625266","title":"异动快报:海正药业(600267)7月20日9点53分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2652625266","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652625266?lang=zh_cn&edition=full","pubTime":"2026-07-20 09:55","pubTimestamp":1784512535,"startTime":"0","endTime":"0","summary":"证券之星7月20日盘中消息,9点53分海正药业(600267)触及涨停板。其所属行业化学制药目前上涨。领涨股为益方生物。该股为PD-1抑制剂,浙江国企改革,国企改革概念热股,当日PD-1抑制剂概念上涨2.41%,浙江国企改革概念上涨1.54%,国企改革概念上涨1.38%。7月17日的资金流向数据方面,主力资金净流出6899.56万元,占总成交额11.1%,游资资金净流出1898.11万元,占总成交额3.05%,散户资金净流入8797.67万元,占总成交额14.15%。近5日资金流向一览见下表:海正药业主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000005786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600267","BK0028","BK0188","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652130237","title":"每周股票复盘:海正药业(600267)获来特莫韦片注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2652130237","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652130237?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:29","pubTimestamp":1784395747,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘,海正药业报收于11.32元,较上周的10.77元上涨5.11%。本周,海正药业7月15日盘中最高价报12.27元。来自公司公告汇总:海正药业将于2026年7月20日召开临时股东会审议TISA-818合作事项。浙江海正药业股份有限公司收到国家药监局核准签发的来特莫韦片《药品注册证书》,批准注册为化学药品4类,视同通过一致性评价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600267","BK0060","BK0239","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651663117","title":"海正药业(600267)披露引进TISA-818系统给药制剂权益协议,7月13日股价上涨5.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651663117","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651663117?lang=zh_cn&edition=full","pubTime":"2026-07-13 22:11","pubTimestamp":1783951880,"startTime":"0","endTime":"0","summary":"截至2026年7月13日收盘,海正药业报收于11.33元,较前一交易日上涨5.2%,最新总市值为133.72亿元。近日,浙江海正药业股份有限公司拟与艾缇亚(上海)制药有限公司签署产品独家授权许可及合作协议,引进化药1类TISA-818系统给药制剂在中国大陆、香港和澳门地区的开发、注册、生产和商业化权益。海正药业将支付4500万元首付款,累计最高不超过1亿元的开发里程碑付款,以及基于年净销售额的销售权益金和最高不超过2亿元的销售里程碑奖励金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300039996.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0060","BK0239","BK0028","600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651916665","title":"股市必读:海正药业(600267)预计2026年1-6月扣非后净利润盈利4.9亿元至5.3亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651916665","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651916665?lang=zh_cn&edition=full","pubTime":"2026-07-13 02:28","pubTimestamp":1783880890,"startTime":"0","endTime":"0","summary":"业绩披露要点业绩预告海正药业发布业绩预告,预计2026年1-6月扣非后净利润盈利4.9亿元至5.3亿元;归属净利润盈利6亿元至6.5亿元。公司公告汇总浙江海正药业股份有限公司2026年半年度业绩预增公告浙江海正药业股份有限公司预计2026年半年度实现归属于上市公司股东的净利润为60,000万元到65,000万元,与上年同期相比增加100.62%到117.34%;扣除非经常性损益后的净利润为49,000万元到53,000万元,同比增长52.54%到64.99%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300001236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650154126","title":"每周股票复盘:海正药业(600267)上半年净利预增超100%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650154126","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650154126?lang=zh_cn&edition=full","pubTime":"2026-07-12 02:46","pubTimestamp":1783795570,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘,海正药业报收于10.77元,较上周的10.53元上涨2.28%。本周,海正药业7月6日盘中最高价报10.95元。本周关注点来自业绩披露要点:海正药业预计2026年上半年归母净利润为6亿元至6.5亿元,同比增长超100%。公司公告汇总浙江海正药业股份有限公司预计2026年半年度实现归母净利润60,000万元到65,000万元,同比增长100.62%到117.34%;扣非净利润为49,000万元到53,000万元,同比增长52.54%到64.99%。海正药业披露关于参股子公司担保逾期事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000946.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600267","BK0028","BK0188","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650136879","title":"海正药业(600267)披露2026年半年度业绩预增公告,7月10日股价上涨3.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650136879","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650136879?lang=zh_cn&edition=full","pubTime":"2026-07-10 22:36","pubTimestamp":1783694175,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘,海正药业报收于10.77元,较前一交易日上涨3.26%,最新总市值为127.12亿元。该股当日开盘10.39元,最高10.84元,最低10.21元,成交额达3.55亿元,换手率为2.82%。近日,浙江海正药业股份有限公司发布2026年半年度业绩预增公告。公告显示,公司预计2026年半年度实现归属于上市公司股东的净利润为60,000万元到65,000万元,与上年同期相比增加100.62%到117.34%;扣除非经常性损益后的净利润为49,000万元到53,000万元,同比增长52.54%到64.99%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000044752.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0060","600267","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650569181","title":"海正药业:预计2026年1-6月扣非后净利润盈利4.9亿元至5.3亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2650569181","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650569181?lang=zh_cn&edition=full","pubTime":"2026-07-10 18:01","pubTimestamp":1783677680,"startTime":"0","endTime":"0","summary":"证券之星消息,海正药业发布业绩预告,预计2026年1-6月扣非后净利润盈利4.9亿元至5.3亿元。报告期内,公司对外转让浙江省医药工业有限公司100%股权,使得本期非经常性损益同比增加。海正药业2026年一季报显示,一季度公司主营收入23.9亿元,同比下降9.17%;归母净利润3.56亿元,同比上升83.13%;扣非净利润2.36亿元,同比上升29.43%;负债率33.43%,投资收益1.75亿元,财务费用1523.06万元,毛利率50.87%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000034445.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650189126","title":"海正药业最新公告:预计2026年半年度净利润同比增长101%-117%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650189126","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650189126?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:49","pubTimestamp":1783676989,"startTime":"0","endTime":"0","summary":"海正药业(600267.SH)公告称,预计2026年半年度归属于上市公司股东的净利润为6.00亿元-6.50亿元,同比增长101%-117%。业绩变动主要系核心业务板块经营平稳,创新药、原料药及宠物药销售增长,生产规模效应带动成本下降,以及转让浙江省医药工业有限公司100%股权增加非经常性损益。注:公司Q2净利润预计2.44亿-2.94亿,Q1净利润3.56亿,据此计算,Q2净利润预计环比下降17%-31%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000032410.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648668080","title":"海正药业最新公告:签署TISA-818独家授权许可及合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2648668080","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648668080?lang=zh_cn&edition=full","pubTime":"2026-07-03 18:41","pubTimestamp":1783075262,"startTime":"0","endTime":"0","summary":"海正药业(600267.SH)公告称,公司与艾缇亚签署产品独家授权许可及合作协议,引进化药1类创新药TISA-818系统给药制剂在中国大陆、香港和澳门地区的开发、注册、生产和商业化权益。首付款4500万元,开发里程碑付款累计最高不超过1亿元,销售里程碑奖励金累计最高不超过2亿元。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300037745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","600267","BK0028","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647900534","title":"海正药业(600267)披露来特莫韦原料药获上市批准通知书,6月30日股价下跌2.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647900534","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647900534?lang=zh_cn&edition=full","pubTime":"2026-06-30 17:54","pubTimestamp":1782813244,"startTime":"0","endTime":"0","summary":"截至2026年6月30日收盘,海正药业报收于10.11元,较前一交易日下跌2.22%,最新总市值为119.33亿元。浙江海正药业股份有限公司近日收到国家药品监督管理局核准签发的来特莫韦原料药《化学原料药上市申请批准通知书》,该原料药通过CDE技术审评,登记号为Y20240001247,包装规格为20kg/袋,审批结论为符合药品注册要求,批准注册。来特莫韦用于预防接受异基因造血干细胞移植的巨细胞病毒血清学阳性患者的巨细胞病毒感染和疾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000033741.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0060","BK0188","600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647322935","title":"海正药业(600267.SH):来特莫韦原料药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2647322935","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647322935?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:46","pubTimestamp":1782722812,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海正药业(600267.SH)发布公告,近日,公司收到国家药品监督管理局核准签发的来特莫韦原料药的《化学原料药上市申请批准通知书》。来特莫韦适用于接受异基因造血干细胞移植(HSCT)的巨细胞病毒(CMV)血清学阳性的成人和6个月及以上且体重≥6kg的儿童受者[R+]预防巨细胞病毒感染和巨细胞病毒病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460322.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0188","IPOS","600267","BK0060","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786479060009,"stockEarnings":[{"period":"1week","weight":0.1399},{"period":"1month","weight":0.286},{"period":"3month","weight":0.2321},{"period":"6month","weight":0.3447},{"period":"1year","weight":0.2618},{"period":"ytd","weight":0.429}],"compareEarnings":[{"period":"1week","weight":0.0293},{"period":"1month","weight":-0.0155},{"period":"3month","weight":-0.0727},{"period":"6month","weight":-0.0484},{"period":"1year","weight":0.0786},{"period":"ytd","weight":-0.0088}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江海正药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"47673人(较上一季度减少6.51%)","perCapita":"24757股","listingDate":"2000-07-25","address":"浙江省台州市椒江区外沙路46号","registeredCapital":"118027万元","survey":" 浙江海正药业股份有限公司的主营业务是化学原料药和制剂的研发、生产和销售业务。公司的主要产品是抗肿瘤药、抗感染药、心血管药、抗寄生虫药及兽药、内分泌药、其他药品、医药商业、CMO/CDMO/CRO业务、其他。公司入选中国医药工业信息中心“2025年中国医药研发产品线工业企业优秀案例”、2024年度中国医药工业百强榜、人民网“2025人民企业社会责任案例”;获得第90届药交会“首届创新药上市解决方案大赛”综合实力奖,入选2025中国制药工业TOP101榜单;荣膺EcoVadis铜牌认证,可持续发展实践获国际认可;子公司瀚晖制药荣获“浙江省先进级智能工厂”认定;澐生合成荣获BRCGSA级认证,打造合成生物学质量新标杆。","listedPrice":11.83},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海正药业(600267)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海正药业(600267)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海正药业,600267,海正药业股票,海正药业股票老虎,海正药业股票老虎国际,海正药业行情,海正药业股票行情,海正药业股价,海正药业股市,海正药业股票价格,海正药业股票交易,海正药业股票购买,海正药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海正药业(600267)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海正药业(600267)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}